

Sheet 1 of 1

INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION: LIST OF ART CITED	Docket No. 010072.02	Application Number: 10/683,952
	First Named Inventor: Michael J. Sherrill	
	Filing Date: Oct. 9, 2003	Group Art Unit: 1623

US PATENTS AND PUBLISHED APPLICATIONS					
Examiner Initial	Item No.	Document Number	Issue/Pub. Date (mm/dd/yyyy)	First Name Inventor	Cited at (if cited in specification)
MCH	A03	2005/0148543 A1	07/07/2005	Sherrill et al.	

US UNPUBLISHED APPLICATIONS					
Examiner Initial	Item No.	Document Number	Filing Date (mm/dd/yyyy)	First Name Inventor	Cited at (if cited in specification)

FOREIGN PATENT DOCUMENTS						
Examiner Initial	Item No.	Document Number	Date (mm/dd/yyyy)	Country	Translation enclosed?	Cited at (if cited in specification)
MCH	C01	WO 99/39694 A2	08/12/1999	PCT	n/a	[0006]
mch	C02	WO 02/066033 A1	08/29/2002	PCT	n/a	[0005]
mch	C03	WO 02/066038 A1	08/29/2002	PCT	n/a	[0005]

NON-PATENT DOCUMENTS				
Examiner Initial	Item No.	Details of Document (AUTHOR, Title, Date, Pertinent Pages, etc.)	Translation enclosed?	Cited at (if cited in specification)
MCH	D01	Chou et al., Proc. Natl. Acad. Sci. USA, 1998, 95, 15798-15802, "Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel"	n/a	[0006]
MCH	D02	Demario et al., J. Clinical Oncology, 1998, 16 (7), 2557-2567, "Oral Chemotherapy: Rationale and Future Directions"	n/a	[0005]
MCH	D03	Sigma-Aldrich on-line catalog, product P1754, "TWEEN 80" (polyoxyethylenesorbitan monooleate), accessed 10/14/2005	n/a	

**** END OF LIST ****

Examiner Signature 	Date considered 4/10/06
-------------------------------	-----------------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Please include copy of this form with next communication to the applicant.

Item No. is Applicant's unique citation designation number for each document.